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Abstract
Objective—To determine whether vitamin D levels are associated with menopause-related 
symptoms in older women.
Methods—A randomly selected subset of 1,407 women, among 26,104 potentially eligible 
participants of the Women’s Health Initiative Calcium and Vitamin D (CaD) trial of 
postmenopausal women aged 51-80 years, had 25-hydroxyvitamin D [25(OH)D] levels measured 
at the CaD trial baseline visit. Information about menopause-related symptoms at baseline was 
obtained by questionnaire and included overall number of symptoms and composite measures of 
sleep disturbance, emotional well-being, and energy/fatigue, as well as individual symptoms. After 
exclusions for missing data, 530 women [mean age 66.2 years (SD 6.8)] were included in these 
analyses.
Results—There were borderline significant associations between 25(OH)D levels and total 
number of menopausal symptoms (p values ranging from 0.05 to 0.06 for fully adjusted models); 
however, the effect was clinically insignificant and disappeared with correction for multiple 
testing. There were no associations between 25(OH)D levels and composite measures of sleep 
disturbance, emotional well-being, or energy/fatigue (p’s > 0.10 for fully adjusted models).
Conclusions—There was no evidence of a clinically important association between serum 
25(OH)D levels and menopause-related symptoms in postmenopausal women.
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Introduction
Many women experience menopause-related symptoms long after the final menstrual period. 
For example, women often experience hot flashes (1-7) for 4 to 10 years post-
menopause (8-10). Many also have mood disturbances, although the link with menopause is 
less clear (1; 6; 7; 11-16). These symptoms can be severe enough to negatively impact quality 
of life, work performance, and personal relationships (1; 17-20). Current treatments for 
menopause-related symptoms, such as menopausal hormone therapy, antidepressants, and 
anticonvulsants, may have significant side effects and serious long-term adverse 
consequences (21-23). After discontinuing treatment, symptoms may recur or even develop de 
novo (24; 25). Recognizing the possible mechanisms underlying menopause-related 
symptoms may lead to the development of new therapeutic strategies.
Calcium balance studies have shown that calcium absorption declines with menopause (26). 
Since 25(OH)D serves the purpose of calcium absorption and appears to be hormonally 
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sensitive, we hypothesized that vitamin D also may influence vasomotor symptoms, which 
are clearly related to hormone levels. Also, some of the symptoms associated with vitamin D 
deficiency, such as mood disturbance and musculoskeletal complaints (27), are similar to 
symptoms women may experience during the transition through menopause (28). We 
therefore hypothesized that vitamin D levels may be associated with menopause-related 
symptoms.
We are unaware of any previous data on this association in postmenopausal women. We did 
find a small study conducted in middle-aged women taking aromatase inhibitors (AIs) for 
breast cancer (29). Although the hot flashes that occur with AI therapy are different than 
menopause-related vasomotor symtpoms, breast cancer patients who had higher 25-
hydroxyvitamin D [25(OH)D] levels (>66 ng/ml) had fewer hot flashes and other symptoms 
compared to women with lower vitamin D levels.
There is some biological data suggesting that a link between vitamin D and menopause-
related symptoms is plausible. Vitamin D can protect against experimental serotonin 
depletion in rats (30) and a menopausal decline in serotonin, a neurotransmitter with known 
effects on thermoregulation, may be a contributor to hot flashes (31-33). In addition, estrogen 
increases the activity of the enzyme responsible for activating vitamin D (34) and so 
declining estrogen levels during the menopausal transition could lead to symptoms of 
vitamin D deficiency. Indeed, vitamin D supplementation can improve mood in 
nonmenopausal populations (29; 35-37).
Based on the totality of evidence from limited data, we hypothesized that higher levels of 
vitamin D would be associated with fewer menopause-related symptoms. To test this 
hypothesis, we examined the cross-sectional association between baseline serum 25(OH)D 
levels and menopausal symptoms in a subset of women who participated in the Women’s 
Health Initiative Calcium and Vitamin D (CaD) trial.
METHODS
This paper presents post–hoc secondary analyses of the association between serum 25(OH)D 
concentrations and menopause-related symptoms in the participants of the WHI calcium and 
vitamin D trial (CaD) trial.
Sample selection
The WHI clinical trials (WHI-CT) enrolled postmenopausal women aged 50 to 79 into 
randomized trials of menopausal hormone therapy (HT) (38) and/or dietary 
modification(DM) (39). At the Year 1 or Year 2 WHI-CT visit, HT and DM trial participants 
were also invited to participate in a randomized placebo-controlled trial of calcium plus 
vitamin D(CaD trial) (40). A total of 36,282 WHI-CT participants enrolled in the CaD trial. 
For our analysis, we drew participants from the CaD trial and used data from the baseline 
CaD trial visit. A subset of these patients (N=4785) had vitamin D levels drawn as part of 
separate, unrelated case control studies; we only included controls (N=1,407) from these 
studies in our analysis.(41-43)
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We excluded women randomized to hormone therapy as part of the WHI trial, women with 
possible medical conditions associated with vitamin D deficiency (following a 
malabsorption diet, colitis, bowel resections, pancreatic disease, current gall bladder 
problems, and liver disease), or women with conditions that would influence vitamin D 
supplementation (high blood calcium or incident cancer). Of the remaining 26,104 eligible 
participants, 530 had vitamin D levels and had data on important potential confounders 
(described below). These 530 women served as the final analytic sample; 528 of these had at 
least one symptom of mild severity.
The Institutional Review Boards at each participating institution approved all protocols and 
consent forms. All women provided signed informed consent.
Data collection
Menopause-related symptoms—At the CaD trial baseline visit, participants provided 
data on menopause-related symptoms via questionnaires(7)., which contained a checklist 
based on the Postmenopausal Estrogen/Progestin Interventions (PEPI) symptom tool (44) and 
other national surveys and clinical trials (45). The psychosocial forms containing these 
symptom items were reviewed for content validity by nationally recognized behavioral and 
clinical experts and were pretested extensively on age-appropriate women from diverse 
racial/ethnic groups (25).
For this analysis, the following symptoms were analyzed: hot flashes, night sweats, 
dizziness, heart racing or skipping beats, tremors, feeling restless or fidgety, feeling tired, 
difficulty concentrating, forgetfulness, mood swings, vaginal dryness, breast tenderness, 
headaches or migraines, waking up at night, waking earlier than planned, trouble falling 
back to sleep after waking earlier than planned, overall typical sleep quality, restless sleep, 
and energy level. These symptoms have been associated with menopause in previous 
research. For most of the symptoms, participants rated their severity on a 4-point scale, from 
symptom did not occur (score of 1) to did not interfere with usual activities, i.e. mild (score 
of 2), interfered somewhat with usual activities, i.e. moderate (score of 3), or so bothersome 
that usual activities could not be performed, i.e. severe (score of 4). For sleep symptoms, 
participants rated how often they occurred over the past 4 weeks (from none to 5 or more 
times per week).
Our primary outcome was total number of symptoms of any severity (mild, moderate, or 
severe; range from 0 to 20). Secondary outcomes included the energy/fatigue and emotional 
well-being subscales of the SF-36, for which higher scores indicate better health (range from 
0-100) (46; 47), and a sleep disturbance construct (48). The latter was created from 5 questions 
about sleep (trouble falling asleep, waking up several times at night, waking earlier than 
planned, trouble falling back to sleep after waking earlier than planned, and overall typical 
sleep); the summary score ranged from 0 to 20 with a higher score indicating greater sleep 
disturbance. We also examined associations between 25(OH)D levels and each individual 
symptom (of any severity) on the checklist.
Serum 25(OH)D assay—Serum was drawn at the baseline CaD trial visit (Year 1 or 2 of 
the CTs) and processed and stored at −80°C, as previously described (42). Serum 25(OH)D 
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concentrations (nmol/L) were measured by using the DiaSorin LIAISON 
chemiluminescence method (DiaSorin, Stillwater, MN), and the coefficient of variation 
(CV) determined by using blinded controls was 11.8% (49).
Potential confounders—At WHI-CT screening, participants self reported data on 
demographics (race, education) and current or prior medical conditions (thyroid disorders). 
At the CaD trial baseline, participants self reported demographics (i.e. age, years since 
menopause), lifestyle factors (i.e. physical activity, smoking), UV exposure (i.e. Langley’s 
measure of UV exposure) and underwent physical measurements (i.e., height and weight to 
calculate BMI) (40). A standardized, in-person, interviewer-administered form was used to 
collect information on the dose, frequency, and duration of current supplements (i.e. 
calcium, vitamin D) and medication use [i.e. menopausal hormone therapy (HT), selective 
serotonin reuptake inhibitors (SSRI)/ serotonin–norepinephrine reuptake inhibitors (SNRI), 
selective estrogen receptor modulators (SERM), hypnotics/sedatives] at CaD 
baseline (50; 51). If data were not available at CaD baseline (Year 1 visit), data from WHI-CT 
screening were used.
At WHI-CT screening, dietary vitamin D and calcium intakes over the past 3 months were 
estimated from a self-administered food-frequency questionnaire (FFQ) specifically 
designed for WHI (52). The FFQ was also administered at CaD trial baseline (Year 1 of 
WHI-CT), but only in the DM trial. Therefore, dietary vitamin D data collected at CaD trial 
baseline (concurrent with the time serum was obtained for determining 25(OH)D 
concentrations) were used when possible; otherwise reported screening dietary vitamin D 
intake was used. As previously reported, the Pearson correlation coefficient among DM trial 
participants for dietary vitamin D intake at baseline and Year 1 was 0.59 (P < 0.0001) (49).
Statistical Methods—We examined the cross-sectional association between 25(OH)D 
level and symptoms. We examined 25(OH)D cutpoints based on current clinical definitions 
of vitamin D deficiency, insufficiency, and sufficiency (≥ 75, 50 to < 75, 25 to < 50, < 25 
nmol/L)(53) These cut-points were similar to quartile cutpoints.
We compared baseline characteristics according to categories of 25(OH)D using Chi-square 
tests of association for categorical variables and ANOVA F-test tests for continuous 
variables.
The symptom total (primary outcome) was normally distributed and therefore modeled as a 
continuous outcome according to 25(OH)D status using general linear models. The 
reference group was ≥75 nmol of 25(OH)D. These results were adjusted for age and race 
and then adjusted for multiple confounding variables chosen a priori based on literature 
review and expert opinion about factors associated with menopausal symptoms and/or 
vitamin D status. These included years since menopause, education, BMI category, smoking 
status, UV exposure, HT at screening (personal history of HT use at the screening visit), trial 
arm (HT or DM), and calcium and vitamin D intake (through diet and supplement).
Using logistic regression, we estimated the odds ratio of having each individual symptom 
according to 25(OH)D status (≥ 75, 50 to < 75, 25 to < 50, < 25 nmol/L), using the highest 
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cut-off as the referent (≥ 75 nmol/L). We first adjusted for race and age and then adjusted 
the models for the potential confounders listed above. We also examined the relationship 
between continuous 25(OH)D levels and continuous number of symptoms and composite 
symptom scores using linear regression.
We did a multiple imputation analysis as a sensitivity analysis to retain the 1407 women 
with 25(OH)D levels regardless of whether they had complete data on confounders.
For both logistic regression and linear models, we examined p values adjusting for multiple 
comparisons for all analyses using a 5% false discovery rate using the Benjamini-Hochberg 
method (54).
This study is a post-hoc analysis of an existing dataset with fixed sample size. Assuming the 
total number of symptoms was the primary outcome of interest and the parameter of interest 
was the regression coefficient of 25(OH)D, we conducted power analyses for two-tailed 
linear multiple regression. With 16 predictors and N=530, we had 80% power at α=0.05 to 
detect an effect size of 0.014. Thus we were able to detect a difference of 0.014 in symptoms 
for each unit change in 25(OH)D.
RESULTS
Baseline characteristics
Women were, on average, 66 years of age and almost 16 years since menopause. 
Participants’ age, years since menopause, education, UV exposure, HT use pattern at 
screening, and randomization to diet modification trial arm did not differ by 25(OH)D status 
(Table 1). A higher percentage of nonwhite, obese, nonsmokers with lower activity levels 
and lower calcium and vitamin D intake (especially from supplements) were in the lower 
two 25(OH)D level categories. There were no differences in the use of relevant non-
hormonal medications (i.e. serotonin–norepinephrine reuptake inhibitors, selective serotonin 
re-uptake inhibitors, selective estrogen receptor modulators, or hypnotics/sedatives) among 
25(OH)D categories, although few women used these medications (<5% of women took at 
least one of these medications; data not shown). There was also no difference in distribution 
of thyroid disease among categories (only 1.8% and 15% had ever had overactive or 
underactive thyroid disease, respectively; data not shown).
Women had from 0 to 17 symptoms of at least mild intensity with a mean of 5.9 (SD 3.3) 
and median of 5 (IQR 5). Only 87 women (16.3%) reported hot flashes and 109 (20.4%) 
reported night sweats.
Association between vitamin D status and overall number and composite measures of 
menopause-related symptoms
We observed no statistically significant association between total number of menopausal 
symptoms and 25(OH)D status in age and race adjusted (p= .11) or fully adjusted (p=0.06) 
models (Table 2). Similarly, we observed no significant association between 25(OH)D status 
and scores on composite measures of sleep disturbance, emotional well-being, and energy/
fatigue in age and race adjusted (p’s>0.05) or fully adjusted models (p’s>0.10). Any 
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associations of borderline statistical significance were no longer significant after adjustment 
for multiple comparisons (data not shown).
Using linear regression, we observed a statistically significant association between 
continuous 25(OH)D levels and total number of symptoms and composite symptom scores. 
Vitamin D levels were not associated with any composite symptom score. In terms of total 
number of symptoms, each 1 nmol/L increase in 25(OH)D level resulted in .01 fewer total 
number of symptoms. This degree of symptom reduction is unlikely to be clinically 
significant. In addition, the association was no longer statistically significant after 
adjustment for multiple comparisons.
Association between 25(OH)D status and individual menopause-related symptoms
No individual menopause-related symptoms were significantly associated with 25(OH)D 
status after adjustment for multiple comparisons (Table 3).
DISCUSSION
In postmenopausal women with an average age of 66 and 15.9 years since menopause. we 
found a borderline association between total number of menopause-related symptoms and 
25(OH)D level. However, the effect size was clinically insignificant and the associations 
were no longer significant after correction for multiple comparisons.
We are unaware of any other studies that have examined the association between vitamin D 
and menopause-related symptoms. In breast cancer patients on aromatase inhibitors, low 
25(OH)D levels were associated with a greater prevalence of symptoms, especially 
vasomotor symptoms;(29) however hot flashes in breast cancer patients are different than 
those in postmenopausal women. Also, the mean age of our population, 66.2 years (SD 6.8), 
was higher than in the study of breast cancer patients (56 years) and we excluded women 
with a history of cancer. In fact, only 27% of the women in our study suffered from any hot 
flashes or night sweats. This low symptom prevalence could have been due to women 
having an average age of 66 and being almost 16 years postmenopause; in addition, women 
with severe menopause-related symptoms were discouraged from participating because of 
the possibility that they might be randomized to placebo.
We had hypothesized that because estrogen increases the activity of the enzyme responsible 
for activating vitamin D (34), low estrogen levels in postmenopausal women could 
exacerbate the symptoms of subclinical vitamin D deficiency, including mood disturbances. 
Previous studies have found that vitamin D supplementation can improve such things as 
mood in nonmenopausal populations (29; 35-37). However, we did not find an association 
between 25(OH)D status and composite scores on sleep, emotional well-being, or energy/
fatigue constructs in our population of postmenopausal women.
There were several limitations of our study. This was a posthoc analysis of women who had 
vitamin D testing done as part of 3 nested case control studies of fracture, breast cancer, and 
colorectal cancer. Participants were matched on age, race-ethnicity, blood draw date, and 
clinic center at CaD randomization. The breast cancer nested case-control study was also 
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matched on HT and DM trial arm participation. This subset selection increased the age of 
the study cohort and reduced the number of women with symptoms related to early 
menopause (such as hot flashes and night sweats). Three-quarters of our participants were 
more than 10 years postmenopausal and women in this study who were still experiencing 
symptoms may not be representative of the general population of women who experience 
symptoms during the transition through menopause. WHI used a brief self-report instrument 
to collect data on menopausal symptoms. Only the presence and broad severity of the 
symptom could therefore be assessed. Given that few women with vasomotor symptoms 
were included in this sample and the lack of rigorous measurement of vasomotor symptoms, 
we cannot exclude a different finding in a younger population with more rigorous 
monitoring of hot flashes.
Because no data on a possible association between vitamin D and menopause-related 
symptoms were available, we examined multiple symptoms. This increased the possibility 
that we would find an association by chance and indeed, when we corrected for multiple 
comparisons, any associations we had found were no longer significant. On the other hand, 
the number of women who were in our final sample was relatively small and only 27% 
suffered from vasomotor symptoms. This low number of women with vasomotor symptoms 
could have limited our ability to see an association between vasomotor symptoms and 
25(OH)D. We did perform sensitivity analyses using multiple imputation to examine all 
1407 women with 25(OH)D levels (not just those who had data on confounders) and had 
similar null findings. We did not stratify by time since menopause and it is possible that 
25(OH)D may be associated with menopausal symptoms in women closer to the onset of 
menopause. Because this was a post hoc analysis, conclusions can only be considered 
hypothesis generating.
CONCLUSION
Our data does not support the hypothesis that vitamin D status is associated with 
menopause-related symptoms in postmenopausal women with an average age of 66. We 
cannot exclude an association in younger women who are more symptomatic.
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Figure 1. 
Flow of WHI participants into study cohort
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